-
Clinicians’ beliefs and awareness of substance abuse treatments in research- and nonresearch-affiliated programs.
Arfken CL, Agius E, Dickson MW, Anderson HL, Hegedus AM. Clinicians' beliefs and awareness of substance abuse treatments in research- and nonresearch-affiliated programs. Journal of Drug Issues 2005;35(3):547-558.
-
Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs.
Saxon AJ, McCarty D. Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacology & Therapeutics 2005;108:119-128.
-
Multi-level assessment protocol (MAP) for adoption in multisite clinical trials.
Guydish J, Manswer ST, Jessup MA, Tajima B, Sears C, Montini T. Multi-Level Assessment Protocol (MAP) for Adoption in Multisite Clinical Trials. Journal of Drug Issues 2005;35(3):529-546.
-
Something of value: The introduction of contingency management interventions into the New York City Health and Hospital Addiction Treatment Service.
Kellogg SH, Burns M, Coleman P, Stitzer M, Wale JB, Kreek MJ. Something of value: The introduction of contingency management interventions into the New York City Health and Hospital Addiction Treatment Service. Journal of Substance Abuse Treatment 2005;28:57-65.
-
Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A National Drug Abuse Treatment Clinical Trials Network Study.
Petry NM, Peirce JM, Stitzer ML, Blaine J, Roll JM, Cohen A, et al. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A National Drug Abuse Treatment Clinical Trials Network Study. Archives of General Psychiatry 2005; 62(10):1148-1156.
-
Stakeholders in recovery: Demands, expectations, and research opportunities.
McCarty D, Zammarelli L, Wylie H, Greenlick MR. Stakeholders in recovery: Demands, expectations, and research opportunities. NIDA Science & Practice Perspectives 2005;3(1):34-37.
-
Evidence-based treatment: Why, what, where, when, and how?
Miller WR, Zweben J, Johnson WR. Evidence-based treatment: Why, what, where, when, and how? Journal of Substance Abuse Treatment 2005;29:267-276.
-
A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network.
Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005; 100(8):1090-1100.
-
Brief Strategic Family Therapy.
Horigian V, Robbins MS, Szapocznik J. Brief Strategic Family Therapy. Brief Strategic and Systemic Therapy European Review 2004;1:251-271.
-
Statistical issues in multisite effectiveness trials: The case of Brief Strategic Family Therapy for adolescent drug abuse treatment.
Feaster DJ, Robbins MS, Horigian V, Szapocznik J. Statistical issues in multisite effectiveness trials: The case of Brief Strategic Family Therapy for adolescent drug abuse treatment. Clinical Trials 2004; 1:428-439.